Updated on 24 August 2026
Human Respiratory Organoid Platform & Applications
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)
About
BiomOrgan 以呼吸道类器官平台为核心,围绕生物医学研究与创新药研发需求,形成多元化、可持续的主营业务体系,主要包括:
1. 科研服务(Research Services)
1) 为高校、科研机构及生物医药企业提供基于呼吸道类器官的疾病模型构建、药物筛选、毒性评估与机制研究服务
2) 支持呼吸系统疾病、病毒感染、慢性疾病等方向的研究需求
3) 提供试剂盒与硬件解决方案
2. 技术产品与解决方案
1) 提供高一致性、高稳定性的类器官培养体系与配套产品
2) 输出标准化、可复制的类器官技术方案,降低科研与药物研发门槛
3) 提供即用型类器官及类器官培养病毒产品
4) 正在与香港玛丽医院建立合作关系,启动肿瘤类器官精准用药筛选合作项目
3. 专利授权与联合开发
1) 通过专利许可、技术授权、联合研发等方式,与制药公司、生物技术公司、AI制药企业开展深度合作
2) 参与合作项目后期收益分成或里程碑付款,提升公司长期价值
Project Location
- China (Hong Kong)
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 5,000,001 to 7,500,000 USD
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Direct Equity Investment
- Open for Negotiation
Preferred Financing Model
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Government & Public Funding
Main Service(s) Required
- Financial Services
Financial Services
- Private Equity & Venture Capital
Attached files
Similar opportunities
Project
通用型人类多能干细胞来源胰岛类器官糖尿病根治性疗法 (Off-the-shelf Stem Cell-derived Islet Organoid Therapy for Diabetes Cure)
- No
- Yes
- Equity
- Technology
- Equity (private)
- Financial Services
- Professional Services
- Minority Shareholdings
- Direct Equity Investment
- 25,000,001 to 50,000,000 USD
- 25,000,001 to 50,000,000 USD
- Investment / Financing Discussion
- Public-Private Partnership Project
Yi HE
CTO at 周易生物
China (Hong Kong)
Project
通用型人类多能干细胞来源胰岛类器官糖尿病根治性疗法 (Off-the-shelf Stem Cell-derived Islet Organoid Therapy for Diabetes Cure)
- No
- Yes
- Equity
- Bio-Tech
- Technology
- IP Related
- Legal Advisory
- Equity (private)
- Medical Technology
- Financial Services
- Financial Advisory
- Professional Services
- Minority Shareholdings
- Corporate Intelligence
- Direct Equity Investment
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
- Public-Private Partnership Project
彬 杨
CEO at 周易生物
China (Hong Kong)